Physician profile

John M Miles

Endocrinology, Diabetes & Metabolism · Kansas City, KS

NPI 1164494233

$12,807.10

in general payments reported to CMS, 2019-2025

19 companies · $217 in 2025

The $217 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$628.01

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $5,123.91 2019-2025 Ozempic, Rybelsus
Sanofi-Aventis U.S. LLC $3,341.76 2019-2023
Roche Diabetes Care Gmbh $1,875.00 2019
Baxter Healthcare $1,508.08 2019
Lilly USA, LLC $284.11 2019-2025 Zepbound
Xeris Pharmaceuticals, INC. $211.31 2022-2023 Gvoke Hypopen
Fresenius Kabi USA, LLC $108.58 2024 Smoflipid
Alcresta Therapeutics, INC. $90.46 2022
Amarin Pharma, INC. $59.25 2019
Esperion Therapeutics, INC. $51.71 2022
Astrazeneca Pharmaceuticals LP $24.65 2021
Amneal Pharmaceuticals LLC $19.19 2025 Unithroid
Janssen Scientific Affairs, LLC $18.37 2021
Boehringer Ingelheim Pharmaceuticals, INC. $18.17 2021
Merck Sharp & Dohme LLC $16.85 2020
Show all 19 companies
CompanyGeneral paymentsYearsTop products
Medtronic, INC. $15.17 2024 Minimed 780g
Beta Bionics, INC. $15.12 2025 Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset
Abbott Laboratories $13.07 2021
Antares Pharma, INC. $12.34 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John M Miles

$12,807.10

in general payments reported 2019-2025

Years
2019-2025
Top company
Novo Nordisk INC
Context
The $217 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).

https://glasscript.com/doctor/188488/john-m-miles

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.